IN VITRO PROGNOSTIC METHOD
Patent Information
- Application Number
- IT102024000013375
- Authority / Receiving Office
- IT · IT
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-06-11
- Publication Date
- 2026-07-13
- Estimated Expiration
- 2044-06-11
AI Technical Summary
Current diagnostic methods for Alzheimer's disease (AD) and frontotemporal dementia (FTD) only detect the conditions when cognitive decline is irreversible, lacking effective early markers for initiating timely interventions.
An in vitro method involving the extraction and measurement of miR-190b-5p levels in Neural Derived Extracellular Vesicles (NDEVs) isolated from plasma samples to identify early signs of AD and FTD.
Provides a predictive marker for AD and FTD through increased miR-190b-5p levels in NDEVs, enabling early diagnosis and potential therapeutic interventions before cognitive impairment sets in.
Description
“ ” ’ ’ ’ ’ – ’ ’ ’ ’ ’ ’ ’ ’ ’ ’ ’
Claims
1. Method for the predictive diagnosis of dementia associated with neurodegenerative disease, where said method comprises: - Providing a plasma sample from at least one subject under analysis; - Isolating neuronal extracellular vesicles (NDEV) from said sample; - Isolating miRNAs contained in said NDEVs; - Proceeding with a quantitative amplification of miR-190b-5p contained in said miRNAs isolated from said NDEVs and of miR-190b-5p contained in a population of miRNAs made available as a control, where levels of miR-190b-5p measured in said miRNAs from said subject under analysis higher than the levels of miR-190b-5p measured in the control are indicative of an imminent onset of dementia associated with neurodegeneration.
2. The method according to claim 1, wherein said increased levels of miR-190b-5p are measured at least one year before the onset of symptoms.
3. The method according to claim 1 or 2, wherein said dementia associated with neurodegeneration is selected from the group comprising Alzheimer's disease (AD), frontotemporal dementia (FTD), Lewy Body dementia (LBD).
4. The method according to one of claims 1 to 3, wherein said dementia associated with neurodegeneration is selected from the group consisting of AD and FTD.
5. The method according to one of claims 1 to 4, wherein said NDEV are isolated from plasma following precipitation, after removal of fibrin and proteins, and subsequent selection with the anti CD171 antibody.